Global - Oceanick

Global

Risk-Based Monitoring (RBM) That Works: KRIs, Centralized Monitoring, and Documented Oversight

KRI design that produces decisions (not dashboards) Risk-Based Monitoring (RBM) often fails for one of two reasons: KRIs are chosen because they are easy to measure (not because they are meaningful), or thresholds are set without a documented clinical/operational rationale. The goal is to show documented oversight that is

Global

Informed Consent Compliance in 2026: eConsent, Re-Consent, and Inspection-Proof Documentation

Version control and consent package completeness (the preventable findings) Informed consent findings are often basic: wrong version used, missing required signatures, missing documentation of re-consent, or inconsistent consent dates across source and systems. The way to make consent “inspection-proof” is to treat it as a controlled process with clear document

Global

Vendor Oversight in Clinical Trials: Qualification, KPIs, Audits, and Quality Agreements That Hold Up

Vendor qualification: risk-tiering and evidence that your selection was controlled “Vendor oversight” is not just auditing. It’s the full lifecycle of selecting, qualifying, contracting, supervising, and correcting a partner performing delegated trial activities. Inspectors generally expect sponsors to demonstrate that oversight is proportionate to risk and that responsibilities are

Global

Decentralized Clinical Trial (DCT) Compliance: A Sponsor’s Checklist for Home Health, ePRO, Wearables, and Televisits

PI oversight and delegation in decentralized delivery models Decentralized and hybrid trials distribute activities across locations and organizations. Inspection risk increases when the Investigator’s oversight becomes hard to see in the records. The goal is to make oversight explicit through delegation, training, communication pathways, and documented review of critical

Global

Protocol Deviations and CAPA: How to Investigate Root Cause and Prevent Repeat Findings

Deviation taxonomy: classify consistently so trends are meaningful Deviation programs break down when sites and monitors label similar events differently (or when everything is called “minor”). Consistent classification supports risk-based oversight and makes your CAPA system defensible. This content is operational guidance only and not legal advice. 1) Practical classification

Global

TMF/eTMF Excellence: How to Build a Trial Master File That Survives Inspection (Without Drowning Your Team)

TMF planning: define ownership, timeliness, and QC before the first document TMF/eTMF quality is usually determined early: clear filing responsibilities, naming conventions, and a realistic QC model. Without these, teams drift into “we’ll fix it at the end,” which rarely works under inspection timelines. This content is operational

Global

ALCOA+ Data Integrity in Clinical Trials: A Practical Checklist for Sponsors, CROs, and Sites

Applying ALCOA+ across real trial data sources (not just EDC) ALCOA+ is easiest to discuss in theory and hardest to implement across the many systems and data pathways in modern trials. A practical approach is to map ALCOA+ attributes to each major data source and define the controls and evidence

Global

ICH E6(R3) Explained: Practical Changes Sponsors, CROs, and Sites Must Make in 2026

Implementation roadmap: turn ICH E6(R3) concepts into operating practice ICH E6(R3) emphasizes proactive quality management, proportionate oversight, and fit-for-purpose approaches in a complex ecosystem of vendors, systems, and decentralized activities. Practical implementation requires translating principles into roles, procedures, and evidence that can be demonstrated during inspection. This section